Landos Biopharma Inc

Landos Biopharma — Technical Presentation (August 2022)

16 slides from Landos Biopharma's technical presentation, Aug 11, 2022

  1. Slide 1: NX-13 Phase 1b Clinical Trial Data

    NX-13 Phase 1b Clinical Trial Data AUGUST 2022 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, pla

  3. Slide 3: Positive Top-Line Results Highlight Strong Company Momentum

    Positive Top-Line Results Highlight Strong Company Momentum NX-13 PH. 1b in UC *Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only. Support potential of NX-13 as important, new treatment for Ulcerative Colitis (UC) Validate sharpened

  4. Slide 4: Roadmap for NX-13 Development

    Roadmap for NX-13 Development What’s next: Announcing timing and study design for Phase 2 proof of concept trial later this year What we learned in the Phase 1b trial: What we still need to determine: Favorable safety profile and tolerability in active UC across the study Indications of clinical imp

  5. Slide 5: Phase 1b Clinical Trial Data

    NX-13 Phase 1b Clinical Trial Data

  6. Slide 6: NX-13 Overview and Mechanism of Action

    NX-13 Overview Mechanism of Action Drug Profile Recent & Upcoming Milestones Targets NLRX1 pathway, a mitochondrial-associated regulatory NOD-like receptor Orally active and gut-restricted, allowing target engagement within the GI tract Recently completed successful Phase 1b trial Announcing timing

  7. Slide 7: Selectively Targets Novel Target NLRX1 in the Gut

    NX-13 Selectively Targets Novel Target NLRX1 in the Gut

  8. Slide 8: Phase 1b Study Design of NX-13 in Active UC

    Phase 1b Study Design of NX-13 in Active UC Primary Objective: To assess the safety and tolerability of NX-13 after multiple oral dose administration in subjects with active ulcerative colitis (UC) Key Inclusion Criteria: Male and female subjects 18-75 years old; Active UC >90days; Total Mayo Score

  9. Slide 9: Phase 1b Study Design of NX-13 in Active UC

    Phase 1b Study Design of NX-13 in Active UC Group 1: NX-13 250mg IR n=12 Group 4: Placebo n = 4 Week 2 Week 4 EOT Group 3: NX-13 500 mg MR n=12 Week 5 post-treatment Week 2 Week 4 EOT Week 5 post-treatment Week 2 Week 4 EOT Week 5 post-treatment Week 2 Week 4 EOT Week 5 post-treatment Group 2: NX-13

  10. Slide 10: NX-13 Well-Tolerated and Shows Promising Efficacy Signals in Active UC

    NX-13 was Well-Tolerated and Shows Promising Efficacy Signals in Active UC *Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Safety: NX-13 was generally well tolerated, consistent with non-clinical, Phase 1a data Pharmacokinetics:

  11. Slide 11: NX-13 Phase 1b Trial Safety Evaluations

    Subjects with Placebo (n = 4) NX-13 250mg (n=11) NX-13 500mg (n=10) NX-13 500mg MR (n=11) Serious AEs 0 0 0 0 Mild/Moderate TEAEs 1 (20%) 2 (18.2%) 3 (27.3%) 6 (54.5%) GI (abdominal pain, UC worsening, pancreatitis, constipation) 1 (20%) 0 1 (9.1%) 3 (27.3%) Renal (congenital PCKD, increased creatin

  12. Slide 12: Total Mayo Score Change from Baseline

    Total Mayo Score Change from Baseline Clinical Response Defined as CFB of -3, or -30% in Mayo Score Clinical Remission Defined as Mayo Score less than 2, with no subscore above 1 NX-13 Treated Patients Experienced Reductions in Total Mayo Score after 4 weeks IR= Immediate Release; MR= modified relea

  13. Slide 13: Mayo Endoscopy Score Change from Baseline

    Mayo Endoscopy Score Change from Baseline Endoscopic Response (MES CFB -1) Endoscopic Improvement at All Doses Driving Reduction of Mayo Score FCP = Fecal Calprotectin; Normalization defined as an FCP score reduction to below 250. MES = Mayo Endoscopy Score; PROs = Patient Reported Outcomes *Study w

  14. Slide 14: Supported Symptomatic Remission in Rectal Bleeding and Stool Frequency

    NX-13 Supported Symptomatic Remission in Rectal Bleeding and Stool Frequency Patients in the 250mg group had the greatest reduction of Rectal Bleeding and Stool Frequency at 2 weeks, with further reduction at 4 weeks Majority of patients saw complete resolution of BOTH rectal bleeding and stool freq

  15. Slide 15: Fecal Calprotectin (FCP) Change and Normalization

    Week 4 FCP Change from Baseline FCP Normalization (FCP decrease to <250) Fecal Calprotectin (FCP) Change and Normalization FCP = Fecal Calprotectin; Normalization defined as an FCP score reduction to below 250. *Study was not designed or powered for exploratory clinical endpoints therefore results a

  16. Slide 16: NX-13 Well-Tolerated and Shows Promising Efficacy Signals in Active UC

    NX-13 was Well-Tolerated and Shows Promising Efficacy Signals in Active UC *Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Safety: NX-13 was generally well tolerated, consistent with non-clinical, Phase 1a data Pharmacokinetics:

Landos Biopharma — Technical Presentation (August 2022) on 6ix